Statement of Retraction [Self-administrated vaginal 2% lidocaine in-situ gel for pain relief during copper intrauterine device insertion in women with previous caesarean delivery only: a randomised, double-blind placebo-controlled trial]
- PMID: 37589093
- DOI: 10.1080/13625187.2023.2243186
Statement of Retraction [Self-administrated vaginal 2% lidocaine in-situ gel for pain relief during copper intrauterine device insertion in women with previous caesarean delivery only: a randomised, double-blind placebo-controlled trial]
Retraction of
-
Self-administrated vaginal 2% lidocaine in-situ gel for pain relief during copper intrauterine device insertion in women with previous caesarean delivery only: a randomised, double-blind placebo-controlled trial.Eur J Contracept Reprod Health Care. 2021 Apr;26(2):132-138. doi: 10.1080/13625187.2020.1868427. Epub 2021 Feb 4. Eur J Contracept Reprod Health Care. 2021. Retraction in: Eur J Contracept Reprod Health Care. 2023 Oct;28(5):283. doi: 10.1080/13625187.2023.2243186. PMID: 33539256 Retracted. Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources